SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+6.98%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$223M
AUM Growth
+$223M
(+29%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
22.17%
Top 10 Holdings %
Top 10 Hldgs %
40.82%
Holding
94
New
12
Increased
43
Reduced
11
Closed
23
Top Buys
| 1 |
Galapagos
GLPG
|
$7.11M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$6.41M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$6.24M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$5.92M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$4.87M |
Top Sells
| 1 |
Fulcrum Therapeutics
FULC
|
$5.24M |
| 2 |
NextCure
NXTC
|
$3.17M |
| 3 |
Arvinas
ARVN
|
$3.06M |
| 4 |
Insmed
INSM
|
$2.01M |
| 5 |
Erasca
ERAS
|
$1.98M |
Sector Composition
| 1 | Healthcare | 94.76% |
| 2 | Financials | 4.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $11.2M | 4.55% |
1,514,411
+864,492
| +133% | +$6.41M |
|
|
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $11.1M | 4.49% |
80,348
+18,451
| +30% | +$2.54M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.2M | 4.14% |
195,000
+93,110
| +91% | +$4.87M |
|
4
Merus
MRUS
$4.98B
| $10.2M | 4.13% |
320,174
-25,790
| -7% | -$820K |
|
5
Veracyte
VCYT
$2.39B
| $9.12M | 3.7% |
221,362
+41,814
| +23% | +$1.72M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.91M | 3.61% |
60,757
+14,816
| +32% | +$2.17M |
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $8.86M | 3.59% |
1,100,000
+735,000
| +201% | +$5.92M |
|
8
Cogent Biosciences
COGT
$1.69B
| $7.3M | 2.96% |
850,935
+173,035
| +26% | +$1.48M |
|
|
9
Galapagos
GLPG
$2.07B
| $7.11M | 2.88% |
+128,901
| New | +$7.11M |
|
10
Cerus
CERS
$251M
| $7.1M | 2.88% |
1,042,722
+423,353
| +68% | +$2.88M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.65M | 2.69% |
61,700
+9,231
| +18% | +$995K |
|
12
iTeos Therapeutics
ITOS
| $6.43M | 2.6% |
138,006
+21,075
| +18% | +$981K |
|
|
APEN
13
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.24M | 2.53% |
+739,604
| New | +$6.24M |
|
|
RACB
14
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $5.42M | 2.19% |
556,890
+83,494
| +18% | +$812K |
|
15
Immatics
IMTX
$619M
| $5.26M | 2.13% |
391,155
-46,711
| -11% | -$628K |
|
|
LHDX
16
DELISTED
Lucira Health, Inc. Common Stock
LHDX
| $4.43M | 1.8% |
515,000
+294,242
| +133% | +$2.53M |
|
|
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.18M | 1.69% |
192,045
+28,559
| +17% | +$621K |
|
18
Aclaris Therapeutics
ACRS
$209M
| $4.16M | 1.69% |
286,226
+112,899
| +65% | +$1.64M |
|
|
AMYT
19
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $3.78M | 1.53% |
350,213
-166,008
| -32% | -$1.79M |
|
|
CTIC
20
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $3.68M | 1.49% |
+1,483,829
| New | +$3.68M |
|
21
Leap Therapeutics
LPTX
$12M
| $3.28M | 1.33% |
1,013,664
+393,664
| +63% | +$1.28M |
|
22
Krystal Biotech
KRYS
$4.27B
| $3.27M | 1.32% |
+46,670
| New | +$3.27M |
|
|
MORF
23
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.2M | 1.29% |
67,440
+9,736
| +17% | +$461K |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.18M | 1.29% |
111,860
+62,478
| +127% | +$1.78M |
|
25
United Therapeutics
UTHR
$13.8B
| $3.14M | 1.27% |
14,551
-6,638
| -31% | -$1.43M |
|